Subscribe
shutterstock_1425318470_photobyphm
Photobyphm / Shutterstock.com
5 March 2020AmericasSarah Morgan

Sanofi unit takes CSL to court over haemophilia therapy

Biotech company Bioverativ has accused CSL Behring of infringing three patents covering its haemophilia B treatment Alprolix (coagulation factor IX (Recombinant), Fc fusion protein).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sanofi to buy Bioverativ for $11.6bn
23 January 2018   Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.
Americas
USITC begins probe into CSL Behring
10 August 2017   The US International Trade Commission has instituted a probe into CSL Behring, a biopharmaceutical company.
Americas
French healthcare company makes $1.2bn AI drug discovery deal
18 August 2022   Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Sanofi to buy Bioverativ for $11.6bn
23 January 2018   Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.
Americas
USITC begins probe into CSL Behring
10 August 2017   The US International Trade Commission has instituted a probe into CSL Behring, a biopharmaceutical company.
Americas
French healthcare company makes $1.2bn AI drug discovery deal
18 August 2022   Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.

More on this story

Americas
Sanofi to buy Bioverativ for $11.6bn
23 January 2018   Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.
Americas
USITC begins probe into CSL Behring
10 August 2017   The US International Trade Commission has instituted a probe into CSL Behring, a biopharmaceutical company.
Americas
French healthcare company makes $1.2bn AI drug discovery deal
18 August 2022   Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers